Detalhe da pesquisa
1.
Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study.
Haematologica
; 109(4): 1194-1205, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37767550
2.
Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study.
PLoS Med
; 20(6): e1004157, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37384638
3.
A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma.
Blood
; 136(21): 2401-2409, 2020 11 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-32730586
4.
High-dose methotrexate and rituximab induction regimen in immunocompetent patients with primary CNS lymphoma: a retrospective single-center study of survival predictors.
J Neurooncol
; 158(1): 33-40, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35441948
5.
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Lancet
; 396(10254): 839-852, 2020 09 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-32888407
6.
NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020.
J Natl Compr Canc Netw
; 18(5): 522-536, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32380458
7.
Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma.
Am J Hematol
; 95(1): 18-27, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31621094
8.
Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study.
Lancet Oncol
; 20(7): 998-1010, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31101489
9.
PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.
Blood
; 130(2): 221-228, 2017 07 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-28468799
10.
AIDS-Related Kaposi Sarcoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 17(2): 171-189, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30787130
11.
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.
J Natl Compr Canc Netw
; 17(6): 650-661, 2019 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31200358
12.
Congestive heart failure in older adults diagnosed with follicular lymphoma: A population-based study.
Cancer
; 124(21): 4221-4230, 2018 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30303522
13.
Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 16(8): 986-1017, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30099375
14.
NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018.
J Natl Compr Canc Netw
; 16(2): 123-135, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-29439173
15.
C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy.
Cancer
; 123(22): 4411-4418, 2017 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28749548
16.
Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies.
Am J Hematol
; 92(2): 161-170, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27880984
17.
Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma.
Curr Oncol Rep
; 17(9): 41, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26194424
18.
Tivozanib: status of development.
Curr Oncol Rep
; 17(6): 24, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25895472
19.
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma.
BJU Int
; 113(5b): E137-43, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24219029
20.
How do I recommend extended adjuvant hormonal therapy?
Curr Treat Options Oncol
; 15(1): 55-62, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24338340